CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,034,478 | -43.0% | 265,135 | -29.4% | 0.13% | -34.7% |
Q2 2023 | $21,096,738 | +906.4% | 375,788 | +710.8% | 0.20% | +818.2% |
Q1 2023 | $2,096,275 | -7.7% | 46,347 | -17.0% | 0.02% | -12.0% |
Q4 2022 | $2,271,156 | -89.1% | 55,871 | -82.5% | 0.02% | -89.8% |
Q3 2022 | $20,841,000 | +103.5% | 318,910 | +89.3% | 0.24% | +106.8% |
Q2 2022 | $10,239,000 | +10.3% | 168,485 | +13.9% | 0.12% | +40.5% |
Q1 2022 | $9,285,000 | +1802.7% | 147,917 | +4542.7% | 0.08% | +2000.0% |
Q4 2020 | $488,000 | +82.8% | 3,186 | -0.0% | 0.00% | +100.0% |
Q3 2020 | $267,000 | -97.7% | 3,187 | -98.0% | 0.00% | -98.1% |
Q2 2020 | $11,719,000 | +140.0% | 159,458 | +38.5% | 0.10% | +89.1% |
Q1 2020 | $4,882,000 | +4.6% | 115,112 | +50.2% | 0.06% | +61.8% |
Q4 2019 | $4,668,000 | +45.4% | 76,636 | +40.3% | 0.03% | +47.8% |
Q2 2018 | $3,210,000 | – | 54,631 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |